The effects of regular consumption of short-chain fructo-oligosaccharides on digestive comfort of subjects with minor functional bowel disorders

British Journal of Nutrition

Volumn 99, Issue 2, 2008, Pages 311-318

  Paineau, Damien ^a   Payen, Flore ^a   Panserieu, Suzanne ^b   Coulombier, Geneviève ^c   Sobaszek, Annie ^d   Lartigau, Isabelle ^d   Brabet, Marylène ^e   Galmiche, Jean Paul ^f   Tripodi, Dominique ^f   Sacher Huvelin, Sylvie ^f   Chapalain, Véronique ^g   Zourabichvili, Othar ^a   Respondek, Frédérique ^h   Wagner, Anne ^h   Bornet, Francis R J ^a  

^a Nutri Health SA   (France)

^b AVICENNE HOSPITAL   (France)

^c POITIERS UNIVERSITY HOSPITAL   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e HÔPITAL SAINT ELOI   (France)

^f HÔTEL DIEU   (France)

^g Quanta Medical Immeuble Amp re   (France)

^h ZI et Portuaire ^*  (France)

Author keywords

Functional bowel disorders; Quality of life; Short chain fructo oligosaccharides

Indexed keywords

FOS ACTILIGHT; FRUCTOSE OLIGOSACCHARIDE; MALTODEXTRIN; PLACEBO; SUCROSE; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ABDOMINAL SWELLING; ADULT; ANGINA PECTORIS; ANXIETY; ARTICLE; BLOATING; BRONCHITIS; CARBOHYDRATE ANALYSIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFECATION URGENCY; DIARRHEA; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; GASTROENTERITIS; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TRACT FUNCTION; GLUCOSE INTAKE; HUMAN; INFECTION; INTESTINE FUNCTION DISORDER; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORNING DOSAGE; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; SINUSITIS; SKIN TOXICITY; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING;

ACTIVITIES OF DAILY LIVING; ADULT; COLONIC DISEASES, FUNCTIONAL; DIETARY SUPPLEMENTS; DIGESTION; DOUBLE-BLIND METHOD; FEMALE; FRUCTOSE; HUMANS; MALE; OLIGOSACCHARIDES; PATIENT COMPLIANCE; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 38049173966     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S000711450779894X     Document Type: Article

References (43)

1. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ & Müller-Lissner SA (1999) Functional bowel disorders and functional abdominal pain. Gut 45, Suppl. 2, II43-II47.
2. Drossman D, Li Z & Andruzzi E (1993) Householder survey of functional gastrointestinal disorders. Prevalence, socio-demography, and health impact. Dig Dis Sci 38, 1569-1580.
3. Talley N, Weaver AL & Zinsmeister. AR (1995) Impact of functional dyspepsia on quality of life. Dig Dis Sci 40, 584-589.
4. Kettel J, Jones R & Lydeard S (1992) Reasons for consultation in irritable bowel syndrome: Symptoms and patients characteristics. Br J Gen Pract 42, 459-461.
5. Camilleri M & Choi M (1997) Review Article: Irritable bowel syndrome. Aliment Pharmacol Ther 11, 3-15.
6. Frexinos J, Denis P, Allemand H, Allouche S, Los F & Bonnelye G (1998) Descriptive study of digestive functional symptoms in the French general population. Gastroenterol Clin Biol 22, 785-791.
7. Sainsbury A & Heatley RV (2005) Review article: Psychosocial factors in the quality of life of patients with inflammatory bowel disease. Aliment Pharmacol Ther 21, 499-508.
8. Thompson WG, Heaton KW, Smyth GS & Smyth C (1997) Irritable bowel syndrome: The view from general practice. Eur J Gastroenterol Hepatol 9, 689-692.
9. Dapoigny M, Dyard F, Grimaud J, Guyot P & van Ganse E (2003) Troubles fonctionnels intestinaux et consommation de soins. Etude observationnelle en gastroentérologie libérale (Irritable bowel syndrome and healthcare consumption. An observational study in private gastroenterology). Gastroenterol Clin Biol 27, 265-271.
10. Talley N, Gabriel S, Harmsen W, Zinsmeister A & Evans RW (1995) Medical costs in community subjects with irritable bowel syndrome. Gastroenterology 109, 1736-1741.
11. Maxion-Bergemann S, Thielecke F, Abel F & Bergemann R (2006) Costs of irritable bowel syndrome in the UK and US. Pharmacoeconomics 24 21-37.
12. Molis C, Flourié B, Ouarne F, Gailing MF, Lartigue S, Guibert A, Bornet F & Galmiche JP (1996) Digestion, excretion, and energy value of fructooligosaccharides in healthy humans. Am J Clin Nutr 64, 324-328.
13. Bouhnik Y, Raskine L, Simoneau G, Vicaut E, Neut C, Flourié B, Brouns F & Bornet F (2004) The capacity of non-digestible carbohydrates to stimulate fecal bifidobacteria in healthy humans: A double-blind, randomized, placebo controlled, parallel group, dose-response relation study. Am J Clin Nutr 80, 1658-1664.
14. Bouhnik Y, Vahedi K, Achour L, Attar A, Salfati J, Pochart P, Marteau P, Flourié B, Bornet F & Rambaud JC (1999) Short-chain fructo-oligosaccharide administration dose-dependently increases fecal bifidobacteria in healthy humans. J Nutr 129, 113-116.
15. Buddington RK, Williams CH, Chen SC & Witherly SA (1996) Dietary supplement of neosugar alters the fecal flora and decreases activities of some reductive enzymes in human subjects. Am J Clip Nutr 63 709-716.
16. Gibson GR & Roberfroid MB (1995) Dietary modulation of the human colonic microbiota: Introducing the concept of prebiotics. J Nutr 125 1401-1412.
17. Hidaka H (1986) Effects of fructo-oligosaccharides on intestinal flora and human health. Microflora 5, 37-50.
18. Berggren AM, Björck IM, Nyman EM & Eggum BO (1993) Short chain fatty acid content and pH in caecum of rats given various source of carbohydrates. J Sci Food Agri 63, 397-406.
19. Nyman M (2002) Fermentation and bulking capacity of indigestible carbohydrates: The case of inulin and oligofructose. Br J Nutr 87, Suppl. 2, S163-S168.
20. Fich A, Phillips SF, Hakim NS, Brown ML & Zinsmeister AR (1998) Stimulation of ileal emptying by short-chain fatty acids. Dig Dis Sci 34, 1516-1520.
21. Cherbut C, Aube AC, Blottière HM, Pacaud P, Scarpignato C & Galniche JP (1996) In vitro contractile effects of short-chain fatty acids in the rat terminal ileum. Gut 38, 53-58.
22. Cherbut C, Aube AC, Blottière HM & Galmiche JP (1997) Effects of short-chain fatty acids on gastrointestinal motility. Scand J Gastroenterol Suppl 222, 58-61.
23. Drossman DA (1999) The functional gastrointestinal disorders and the Rome II process. Gut 45, Suppl. 2, II1-II5.
24. Drossman DA (2000) The functional gastrointestinal disorders, their diagnosis, and the Rome II process. In Rome II. The Functional Gastrointestinal Disorders: Diagnosis, Pathophysiology and Treatment: A Multinational Consensus, 2nd ed., pp. 1-36 [DA Drossman, E Corazziari, NJ Talley, WG Thompson and WE Whitehead, editors]. McLean, VA: Degnon Associates.
25. Chassany O, Marquis P, Scherrer B, Read N, Finger T, Bergmann J, Fraitag B, Geneve J & Caulin C (1999) Validation of a specific quality of life questionnaire for functional digestive disorders. Gut 4, 527-533.
26. Chang L, Toner BB, Fukudo S, Guthrie E, Locke GR, Norton NJ & Sperber AD (2006) Gender, age, society, culture, and the patient's perspective in the functional gastrointestinal disorders. Gastroenterology 130 1435-1446.
27. Si JM, Yu YC, Fan YJ & Chen SJ (2004) Intestinal microecology and quality of life in irritable bowel syndrome patients. World J Gastroenterol 10, 1802-1805.
28. Bushnell DM, Martin ML, Ricci JF & Bracco A (2006) Performance of the EQ-5D in patients with irritable bowel syndrome. Value Health 9 90-97.
29. Wilhelmsen I (1995) Quality of life in upper gastrointestinal disorders. Scand J Gastroenterol 211, 21-25.
30. Talley NJ, Fett SL & Zinsmeister AR (1994) Gastrointestinal tract symptoms and self-reported abuse: A population-based study. Gastroenterology 107, 1040-1049.
31. Wiklund I, Dimenäs E & Wahl M (1990) Factors of importance when evaluating quality of life in clinical trials. Control Clin Trials 11, 169-179.
32. Patrick DL & Deyo RA (1989) Generic and disease-specific measures in assessing health status and quality of life. Med Care 27, Suppl. 3, S217-S232.
33. Bouhnik Y, Raskine L, Simoneau G, Paineau D & Bornet F (2006) The capacity of short-chain fructo-oligosaccharides to stimulate faecal bifidobacteria: A dose-response relationship study in healthy humans. Nutr J 5, 8.
34. Briet F, Achour L, Flourié B, Beaugerie L, Pellier P, Franchisseur C, Bornet F & Rambaud JC (1995) Symptomatic response to varying levels of fructo-oligosaccharides consumed occasionally or regularly. Eur J Clin Nutr 49, 501-507.
35. Rumessen JJ & Gudmand-Hoyer E (1988) Functional bowel disease: malabsorption and abdominal distress after ingestion of fructose, sorbitol, and fructose-sorbitol mixtures. Gastroenterology 95 694-700.
36. Longstreth G, Thompson W, Chey WD, Houghton LA, Mearin F & Spiller RC (2006) Functional bowel disorders. Gastroenterology 130, 1480-1491.
37. Gwee KA (2005) Irritable bowel syndrome in developing countries - a disorder of civilization or colonization? Neurogastroenterol Motil 1, 317-324.
38. Wilson A, Longstreth G, Knight K, Wong J, Wade S, Chiou C, Barghout V, Frech F & Ofman J (2004) Quality of life of managed care patients with irritable bowel syndrome. Manag Care Interface 17, 24-28.
39. Amouretti M, Le Pen C, Gaudin A-F, Bommelaer G, Frexinos J, Ruszniewski P, Poynard T, Maurel F, Priol G & El Hasnaoui A (2006) Impact of irritable bowel syndrome (IBS) on health-related quality of life (HRQCL). Gastroenterol Clin Biol 30, 241-246.
40. Longstreth G, Wilson A, Knight K, Wong J, Chiou C, Barghout V, Frech F & Ofman J (2003) Irritable bowel syndrome, health care use, and costs: A U.S. managed care perspective. Am J Gastroenterol 98, 600-607.
41. Lindsay JO, Whelan K, Stagg AJ, Gobin P, Al-Hassi HO, Rayment N, Kamm MA, Knight SC & Forbes A (2006) Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn's disease. Gut 55, 348-355.
42. Di Sabatino A, Morera R, Ciccocioppo R, Cazzola P, Gotti S, Tinozzi FP, Tinozzi S & Corazza GR (2005) Oral butyrate for mildly to moderately activate Crohn's disease. Aliment Pharmacol Ther 22, 789-794.
43. Segain JP, Raingeard de la B1étière D, Bourreille A, Leray V, Gervois N, Rosales C, Ferrier L, Bonnet C, Blottiere HM & Galmiche JP (2000) Butyrate inhibits inflammatory responses through NF ΚB inhibition: Implications for Crohn's disease. Gut 47, 397-403.